Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 16/20 | 0.80 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.80 |
| ▸ | PIK3CD | O00329 | 14/20 | 0.72 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.72 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.72 |
| ▸ | MTOR | P42345 | 3/20 | 0.68 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.61 |
| ▸ | PLK4 | O00444 | 1/20 | 0.61 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.61 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.61 |
| ▸ | GAK | O14976 | 1/20 | 0.61 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.61 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.61 |
| ▸ | STK16 | O75716 | 1/20 | 0.61 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.61 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.61 |
| ▸ | NQO2 | P16083 | 1/20 | 0.61 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.61 |
| ▸ | JAK1 | P23458 | 1/20 | 0.61 |
| ▸ | TYK2 | P29597 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190611 | 0.97 | PIK3CA (0.75) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1181219 | 0.92 | PIK3CA (0.67) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1181814 | 0.90 | PIK3CA (0.66) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1857333 | 0.90 | PIK3CA (0.65) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1087264 | 0.89 | PIK3CA (0.64) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL190552 | 0.89 | PIK3CA (0.64) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1284857 | 0.89 | PIK3CA (0.63) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL192042 | 0.89 | PIK3CA (0.63) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL13059937 | 0.89 | PIK3CA (0.81) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL993544 | 0.89 | PIK3CA (0.64) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2214675-B1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH INC (US) | 2013-11-20 | — | — | EP | claimed |
| US-8354528-B2 | Process for making thienopyrimidine compounds | GENENTECH, INC. (US) | 2013-01-15 | — | — | US | claimed |
| CN-101909631-B | Process for making thienopyrimidine compounds | GENENTECH INC | 2012-09-12 | — | — | CN | claimed |
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENETECH, INC | 2010-11-18 | — | — | US | claimed |
| EP-2214675-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | Genentech, Inc. (US) | 2010-08-11 | — | — | EP | claimed |
| WO-2009055730-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH, INC. (US) | 2009-04-30 | — | — | WO | claimed |
| EP-4694893-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME Therapeutics LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024216229-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-4412617-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME Therapeutics LLC (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
| WO-2007129161-A2 | THIENO [3, 2-D] PYRIMIDINE DERIVATIVE USEFUL AS PI3K INHIBITOR | F. HOFFMANN-LA ROCHE AG (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007129161-A2 | THIENO [3, 2-D] PYRIMIDINE DERIVATIVE USEFUL AS PI3K INHIBITOR | F. HOFFMANN-LA ROCHE AG (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007127175-A2 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-08 | — | — | WO | disclosed |
| EP-1812444-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006046035-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3R1 16/4885PIK3CD 2/4885 |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | PIK3CA 6/4885PIK3R1 25/4885PIK3CD 2/4885 |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3R1 15/4885PIK3CD 2/4885 |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | PIK3CA 57/4885PIK3R1 106/4885PIK3CD 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.